- Home
- ESAB vs PTCT Comparison
ESAB vs PTCT Comparison
Compare ESAB & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESAB | PTCT |
|---|---|---|
| Founded | 1904 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.0B |
| IPO Year | 2022 | 2006 |
Fundamental Metrics
Financial Performance| Metric | ESAB | PTCT |
|---|---|---|
| Price | $86.87 | $64.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 15 |
| Target Price | ★ $116.91 | $100.47 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | ★ 1.85 | 0.34 |
| Revenue | ★ $2,842,555,000.00 | $264,734,000.00 |
| Revenue This Year | $7.52 | N/A |
| Revenue Next Year | $9.14 | $8.29 |
| P/E Ratio | ★ $48.42 | $191.37 |
| Revenue Growth | 3.71 | ★ 36.19 |
| 52 Week Low | $62.74 | $58.80 |
| 52 Week High | $137.42 | $90.87 |
Technical Indicators
Market Signals| Indicator | ESAB | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 71.02 | 50.09 |
| Support Level | $82.55 | $60.76 |
| Resistance Level | $94.18 | $70.35 |
| Average True Range (ATR) | 4.34 | 2.84 |
| MACD | 2.20 | 0.46 |
| Stochastic Oscillator | 87.30 | 45.02 |
Price Performance
Historical ComparisonAbout ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.8 billion in revenue in 2025.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.